Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization: Dare Bioscience Inc. (DARE)

Dare Bioscience (DARE) - corporate logo

Dare Bioscience, Inc. (DARE) utilizes an asset-light model that minimizes capital expenditures by operating without its own manufacturing plants. The trajectory of its market capitalization, where the EV/EBITDA ratio equals 0.00, reflects the company's dynamics. Its R&D center develops unique non-hormonal products in underserved niches. Business development relies on global alliances with pharma behemoths to jointly conduct clinical trials and bring drugs to market.

DARE Dare Bioscience: Enterprise Value to EBITDA Ratio in the range 11/23/2025 - 11/10/2026

darebioscience.com - analytical breakdowns and key metrics (DARE)

- stock price and consensus target price:
Stock Quotes Dare Bioscience Inc.|DARE - Consensus Target
- company stock exchange capitalization indicators:
Market Value Daré Bioscience, Inc.|DARE - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Daré Bioscience|DARE - Company Net Assets|Market Capitalization to Book Value Ratio darebioscience.com|DARE - Company Assets
- debt and liquidity data:
Debt to Equity Dare Bioscience, Inc.|DARE - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Daré Bioscience|DARE - Company Aggregate Debt|Debts to Book Capitalization Daré Bioscience, Inc.|DARE - Company Long-Term Debts|Company Short-Term Debt Daré Bioscience|Quick Ratio darebioscience.com
- business earnings and investment ratios data:
DARE - Company Net Income|Future Profit Dare Bioscience, Inc.|DARE - Company Value to Net Income|Forward P/E Multiple Dare Bioscience, Inc.|DARE - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Daré Bioscience, Inc.|DARE - Operating income before deduction of amortization|Earnings per share for the last twelve months Daré Bioscience|DARE - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months darebioscience.com|DARE - Expected net earnings per share growth this year|Earnings growth forecast for next year Dare Bioscience, Inc.
Fundamental company valuation:Dare Bioscience Inc. DARE
Original product of darebioscience.com

The implementation of robotic screening and data automation at Dare Bioscience, Inc. (DARE) impacts the company's EV/EBITDA multiple, reflecting the efficiency of its capital expenditures. This indicator correlates the enterprise value of the business with its operating profit before interest, taxes, depreciation, and amortization, allowing investors to determine whether the asset is overvalued or to identify a systemic crisis in the business model against the backdrop of its debt load.

Competitors of Dare Bioscience, Inc.

Organon Corp - Enterprise Value to EBITDA Ratio|TXMD - Enterprise Value to EBITDA Ratio|PTN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization